Bertrand Damour
Chief Executive Officer at NBE-Therapeutics AG
Profile
Bertrand Damour currently works at NBE-Therapeutics AG, as Chief Executive Officer from 2020.
Mr. Damour also formerly worked at OncoEthix SA, as Chief Executive Officer, Pheon Therapeutics Ltd., as Chief Executive Officer & Director, Cooperatieve Rabobank UA (London Branch), as Head-European Equity Derivatives, J.P.
Morgan & Co. Ltd., as Co-Head-Investment Banking Risk Management, Egalet Ltd., as Chief Financial Officer & Executive Vice President, Bankers Trust & Co., as Principal, Deutsche Bank AG (London Branch), as Principal, and GeneProt, Inc., as Chief Executive & Financial Officer.
Mr. Damour received his Masters Business Admin degree from Northwestern University, graduate degree from Institut d’Administration des Entreprises, and graduate degree from École Nationale Supérieure d'Ingénieurs de Caen.
Bertrand Damour active positions
| Companies | Position | Start |
|---|---|---|
NBE-Therapeutics AG
 NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Chief Executive Officer | 03/08/2020 |
Former positions of Bertrand Damour
| Companies | Position | End |
|---|---|---|
Pheon Therapeutics Ltd.
 Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Chief Executive Officer | 25/07/2023 |
Bankers Trust & Co.
 Bankers Trust & Co. Investment Trusts/Mutual FundsMiscellaneous Part of Deutsche Bank AG, Bankers Trust & Co. is a company that provides trust services. The company is based in New York, NY. | Corporate Officer/Principal | - |
Cooperatieve Rabobank UA (London Branch)
 Cooperatieve Rabobank UA (London Branch) Regional BanksFinance Cooperatieve Rabobank U.A. provides banking services. It offers deposits, personal banking, electronic financial transactions, investment advices, short term and long term credits, and several other services. The company is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Deutsche Bank AG (London Branch)
 Deutsche Bank AG (London Branch) Regional BanksFinance Deutsche Bank AG provides corporate banking and investment services. It offers asset and wealth management, corporate banking and securities and global transaction banking solutions. The company was founded in 1873 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
| J.P. Morgan & Co. Ltd. | Corporate Officer/Principal | - |
Training of Bertrand Damour
| Northwestern University | Masters Business Admin |
| Institut d’Administration des Entreprises | Graduate Degree |
| École Nationale Supérieure d'Ingénieurs de Caen | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
Cooperatieve Rabobank UA (London Branch)
Cooperatieve Rabobank UA (London Branch) Regional BanksFinance Cooperatieve Rabobank U.A. provides banking services. It offers deposits, personal banking, electronic financial transactions, investment advices, short term and long term credits, and several other services. The company is headquartered in London, the United Kingdom. | Finance |
| J.P. Morgan & Co. Ltd. | Finance |
Egalet Ltd.
 Egalet Ltd. Pharmaceuticals: MajorHealth Technology Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom. | Health Technology |
OncoEthix SA
 OncoEthix SA Pharmaceuticals: MajorHealth Technology OncoEthix SA operates as a clinical stage biotechnology company which develops cancer drugs. Its products include OTX008, OTX015, and OTX009. The company was founded by Esteban Cvitkovic, Jeanne Kay Noel, Yves Paternot, and Patrice Herait in March 2007 and is headquartered in Luzern, Switzerland. | Health Technology |
Bankers Trust & Co.
Bankers Trust & Co. Investment Trusts/Mutual FundsMiscellaneous Part of Deutsche Bank AG, Bankers Trust & Co. is a company that provides trust services. The company is based in New York, NY. | Miscellaneous |
Deutsche Bank AG (London Branch)
Deutsche Bank AG (London Branch) Regional BanksFinance Deutsche Bank AG provides corporate banking and investment services. It offers asset and wealth management, corporate banking and securities and global transaction banking solutions. The company was founded in 1873 and is headquartered in London, the United Kingdom. | Finance |
| GeneProt, Inc. | |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Health Technology |
Pheon Therapeutics Ltd.
Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Health Technology |
- Stock Market
- Insiders
- Bertrand Damour
